Literature DB >> 27895329

Cancer immunology community seeks better end points.

Elie Dolgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27895329     DOI： 10.1038/nrd.2016.254

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

1.  Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.

Authors:  M Provencio; E Carcereny; Á Artal
Journal:  Clin Transl Oncol       Date:  2019-03-22       Impact factor: 3.405

2.  PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice.

Authors:  Tobias Gutting; Christian A Weber; Philip Weidner; Frank Herweck; Sarah Henn; Teresa Friedrich; Shuiping Yin; Julia Kzhyshkowska; Timo Gaiser; Klaus-Peter Janssen; Wolfgang Reindl; Matthias P A Ebert; Elke Burgermeister
Journal:  Oncoimmunology       Date:  2018-02-01       Impact factor: 8.110

3.  Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy.

Authors:  Huiya Huang; Yiqi Liu; Weixi Liao; Yubing Cao; Qiang Liu; Yakun Guo; Yinying Lu; Zhen Xie
Journal:  Nat Commun       Date:  2019-10-22       Impact factor: 14.919
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.